iRadimed Corporation (NASDAQ: IRMD - Get Free Report) CEO Roger Susi sold 5,000 shares of the stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $100.38, for a total value of $501,900.00. Following the completion of the transaction, the chief executive officer directly owned 2,235,000 shares

GMED, TCMD and IRMD tap GenAI to boost diagnostics and workflows, but high costs, regulation gaps and macro pressures still weigh on MedTech growth.

ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 38 th Annual Roth Conference.

ISRG, GMED, EW, ALC and IRMD show strong short-term upside as AI tools, acquisitions and new product pipelines fuel growth.

Principal Financial Group Inc. bought a new position in iRadimed Corporation (NASDAQ: IRMD) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 5,927 shares of the medical equipment provider's stock, valued at approximately $422,000. Several other hedge funds have also modified their

Nine Ten Capital Management sold 342,907 shares of IRadimed; the estimated transaction value was $29.42 million based on quarterly average price. The quarter-end position value decreased by $13.21 million, reflecting both share sales and price changes.

For the 18th time in a row, the niche medical device maker set a new all-time high for quarterly revenue. It also handily topped the consensus analyst estimate for adjusted net profit.

IRADIMED CORPORATION (IRMD) Q4 2025 Earnings Call Transcript

ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the quarter and year ended December 31, 2025. The Company is a leader in developing innovative magnetic resonance imaging (“MRI”) compatible medical devices and products. The Company is a provider of (i) non-magnetic intravenous (“IV”) infusion pump systems and (ii) non-magnetic patient vital signs monitoring systems that are each designed for use during MRI procedures.

Shares of iRadimed Corporation (NASDAQ: IRMD - Get Free Report) have been given an average rating of "Moderate Buy" by the five research firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price